Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis

Advanced marginal zone lymphoma (MZL) is an incurable B-cell malignancy dependent on B-cell receptor signaling. The phase 2 PCYC-1121 study demonstrated the safety and efficacy of single-agent ibrutinib 560 mg/d in 63 patients with relapsed/refractory MZL treated with prior rituximab (RTX) or rituxi...

Full description

Saved in:
Bibliographic Details
Published in:Blood Adv
Main Authors: Noy, Ariela, de Vos, Sven, Coleman, Morton, Martin, Peter, Flowers, Christopher R., Thieblemont, Catherine, Morschhauser, Franck, Collins, Graham P., Ma, Shuo, Peles, Shachar, Smith, Stephen D., Barrientos, Jacqueline C., Chong, Elizabeth, Wu, Shiquan, Cheung, Leo W.-K., Kwei, Kevin, Hauns, Bernhard, Arango-Hisijara, Israel, Chen, Robert
Format: Artigo
Language:Inglês
Published: American Society of Hematology 2020
Subjects:
Clinical Trials and Observations
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7686907/
https://ncbi.nlm.nih.gov/pubmed/33227125
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020003121
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items